News Releases

SCOTTSDALE, Ariz.--(BUSINESS WIRE)-- Magellan Health, Inc. (NASDAQ:MGLN) today reported financial results for the third quarter 2014, as summarized below. For the quarter ended September 30, 2014, the company reported net revenue of $923.2 million, segment profit of $62.2 million and net income of $27.1 million, or $1.00 per diluted common share.

Third Quarter Financial Results1

• Revenue increased due to the inclusion of Partners Rx and CDMI in the current year quarter, new business, same store growth and rate increases, partially offset by the loss of revenues associated with terminated contracts.
• Third quarter segment profit increased mainly due to stronger results in the Commercial and Pharmacy Management segments, partially offset by terminated contracts, as well as administrative start-up costs and estimated operating losses for Magellan Complete Care.
• Net income, earnings per share, adjusted net income and adjusted earnings per share decreased mainly due to a higher effective tax rate resulting from the non-deductibility of Health Insurer Fees, lower reversals of tax contingencies, and increased valuation allowances in the current year for certain deferred tax assets, offset by an increase in segment profit. Reversals of tax contingencies affecting the tax provision were $15.6 million in the current year quarter, and $22.7 million in the prior year quarter.

1 Included in the tables issued with this press release are the reconciliations from non-GAAP measures to the corresponding GAAP measures.

2 Segment profit is equal to net revenues less the sum of cost of care, cost of goods sold, direct service costs and other operating expenses, and includes income from unconsolidated subsidiaries, but excludes segment profit or loss from non-controlling interests held by other parties, as well as stock compensation expense.

3 Adjusted net income and adjusted earnings per share reflect certain adjustments made for acquisitions completed after January 1, 2013 to exclude non-cash stock compensation expense resulting from restricted stock purchases by sellers, as well as amortization of identified acquisition intangibles.

As of September 30, 2014, the company had unrestricted cash and investments of $390.8 million, which includes proceeds from the drawdown of the $250 million term loan under the company's new credit facility.

"This has been a transitional year for Magellan," said Barry M. Smith, chairman and chief executive officer of Magellan Health. "We stabilized our business, made important acquisitions, and continued to advance our growth strategies. As we approach the end of the year, we remain firmly focused on the work necessary to achieve our aggressive long-term growth targets as the leader in special population management.

"Our three core businesses - including Magellan Complete Care - provide a broad range of next generation solutions to address today's healthcare challenges and tomorrow's healthcare opportunities. I am extremely pleased that we are anticipating solid growth next year, and are well positioned for continued growth in the future."

Share Repurchase Program

Year-to-date through Tuesday, October 21, 2014, the company repurchased approximately 2.8 million shares for a total cost of $161.8 million, at average price of $57.54, and has completed approximately $277.7 million of the current $300 million authorization. The Board of Directors has authorized a new share repurchase program of up to $200 million over a two year period until October 22, 2016. The shares may be purchased from time-to-time on the open market, under 10b5-1 plans, or in privately negotiated transactions. There are a number of factors that impact the timing and pace of purchases, such as stock price, capital needs, acquisitions and determination of open and closed trading windows.

Results and Outlook

"The third quarter of 2014 was a strong one for Magellan, particularly in our Commercial, Specialty Solutions and Pharmacy Management segments," said Jonathan N. Rubin, chief financial officer. "We resolved the cost of care issues that we experienced on one of our risk behavioral health contracts. The care costs recorded in the quarter for Magellan Complete Care of Florida resulted in an estimated Medical Loss Ratio of approximately 100 percent, which is within the range of our expectations for the start-up phase of the program. It's important to note, however, that these estimates are based on limited data, as we only have leading indicators of drug costs and inpatient pre-authorizations. We expect to have a more complete view of full claims data in early 2015.

"Given the results to date, we are now expecting our full year 2014 guidance for net revenue in the range of $3.6 to $3.8 billion, net income of $63 to $77 million, segment profit in the range of $243 million to $258 million, and cash flow from operations of $207 million to $226 million. Taking into account the impact of share repurchase activity through October 21, 2014, but not considering any potential future share repurchases, our guidance range for fully diluted EPS is estimated to be $2.30 to $2.81, based on a fully diluted share count of 27.4 million. We are also revising our 2014 guidance range for full-year adjusted net income of $88.0 million to $102.0 million. We have updated our guidance for adjusted earnings per share to a range of $3.21 to $3.72, based on the updated fully diluted share count.

"Looking ahead, we expect to have solid segment profit growth in 2015. We will provide detailed 2015 guidance during our December call."

Earnings Conference Call

Management will host a conference call at 10 a.m. Eastern time on Friday, October 24, 2014. To participate in the conference call, interested parties should call 1-800-857-1812 and reference the pass code Third Quarter 2014 Earnings Call approximately 15 minutes before the start of the call. The conference call will also be available via a live webcast at Magellan's investor relations page at MagellanHealth.com.

About Magellan Health: Headquartered in Scottsdale, Ariz., Magellan Health, Inc. is a healthcare management company that focuses on fast-growing, complex and high-cost areas of healthcare, with an emphasis on special population management. Magellan delivers innovative solutions to improve quality outcomes and optimize the cost of care for those we serve. Magellan's customers include health plans, managed care organizations, insurance companies, employers, labor unions, various military and government agencies, third party administrators, consultants and brokers. For more information, visit MagellanHealth.com.

Cautionary Statement

This release contains forward-looking statements within the meaning of the Securities Exchange Act of 1934 and the Securities Act of 1933, as amended, which involve a number of risks and uncertainties. All statements, other than statements of historical information provided herein, may be deemed to be forward-looking statements including, without limitation, statements regarding estimates of 2014 net revenue, net income, adjusted net income, segment profit, cash flow from operations, earnings per share, adjusted earnings per share, capital deployment, 2015 segment profit growth and strategy. These statements are based on management's analysis, judgment, belief and expectation only as of the date hereof, and are subject to uncertainty and changes in circumstances. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "may," "should," "could," "estimate," "intend" and other similar expressions are intended to identify forward-looking statements. Actual results could differ materially due to, among other things, the possible election of certain of the company's customers to manage the healthcare services of their members directly; changes in rates paid to and/or by the company by customers and/or providers; higher utilization of health care services by the company's risk members; delays, higher costs or inability to implement new business or other company initiatives; the impact of changes in the contracting model for Medicaid contracts; termination or non-renewal of customer contracts; the impact of new or amended laws or regulations; governmental inquiries; litigation; competition; operational issues; health care reform; and general business conditions. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the "Risk Factors" section included within the company's Annual Report on Form 10-K for the year ended December 31, 2013, filed with the Securities and Exchange Commission on March 3, 2014, and the company's subsequent Quarterly Reports on Form 10-Q filed during 2014. Readers are cautioned not to place undue reliance on these forward-looking statements. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date of this release. Segment profit information referred to herein may be considered a non-GAAP financial measure. Further information regarding this measure, including the reasons management considers this information useful to investors, are included in the company's most recent Annual Report on Form 10-K and on subsequent Form 10-Qs.

Media:
Colleen Flanagan Johnson, 860-507-1923
cefjohnson@magellanhealth.com
or
Investor:
Renie Shapiro Silver, 877-645-6464
rshapiro@magellanhealth.com

Source: Magellan Health, Inc.

News Provided by Acquire Media